COMMUNIQUÉS West-GlobeNewswire
      -   
  
VALNEVA :Transfert à Oddo BHF du contrat de liquidité initialement conclu avec Natixis
18/07/2018 -   
  
Novartis Kisqali® now first and only CDK4/6 inhibitor indicated in US as first-line therapy specifically for premenopausal women; and as initial therapy with fulvestrant in postmenopausal women
18/07/2018 -   
  
JetBlue Airways to Implement ClimaCell’s New HyperCast Aviation Microweather Software to Increase Safety and Efficiency
18/07/2018 -   
  
Tabula Rasa Healthcare to Announce Second Quarter 2018 Operating Results and Host Conference Call on Tuesday, August 7, 2018
18/07/2018 -   
  
Athenex Announces Axis Therapeutics Has Entered into a MOU with the Hong Kong Polytechnic University to Set Up a Joint Research Center on Cancer Immunotherapy
18/07/2018 -   
  
Tree of Knowledge Goes Public on the CSE Backed by Strong Management Team and Advisory Board -- CFN Media
18/07/2018 -   
  
Devonian Healthcare Group Reports its First ever Revenues: Key Financial Results for Quarter Ended April 30th, 2018
18/07/2018 -   
  
Groupe Santé Devonian rapporte ses premiers revenus : Résultats Financiers clés pour le trimestre terminé le 30 avril 2018
18/07/2018 -   
  
Altasciences Participates in Clinical Trial for Type 1 Diabetes Mellitus
18/07/2018 -   
  
Altasciences participe à un essai clinique sur le diabète sucré de type 1
18/07/2018 -   
  
PositiveID Adds Listeria to Pathogens Detected by FireflyDX Onsite Detection Prototype
18/07/2018 -   
  
HMS Holdings Corp. To Report Second Quarter 2018 Financial and Operating Results
18/07/2018 -   
  
Hemostemix Announces First U.S. Patients Treated in Phase II Clinical Trial
18/07/2018 -   
  
Spectral Announces Successful Manufacturing Audit of Toray by the US FDA
18/07/2018 -   
  
Cellectar Reports Positive Phase 2 Interim Data for CLR 131 in Relapsed/Refractory DLBCL Patients
18/07/2018 -   
  
Taconic Biosciences and Cyagen Biosciences Announce Strategic Partnership
18/07/2018 -   
  
FDA Accepts Biologics License Application for Filing and Grants Priority Review for Sacituzumab Govitecan for the Treatment of Metastatic Triple-negative Breast Cancer
18/07/2018 -   
  
Pediapharm Announces Annual Audited Financial Results – 61% Annual Revenue Growth and 11th Consecutive Year-over-year Quarterly Growth
18/07/2018 -   
  
Pediapharm annonce ses résultats financiers audités annuels - hausse annuelle de 61% des revenus et 11e trimestre consécutif de croissance d’un exercice à l’autre
18/07/2018 
Pages